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Abstract
Controlled clinical trials are widely considered to be the vehicle to treatment discovery in cancer that leads to significant
improvements in health outcomes including an increase in life expectancy. We have previously shown that the pattern of
therapeutic discovery in randomized controlled trials (RCTs) can be described by a power law distribution. However, the
mechanism generating this pattern is unknown. Here, we propose an explanation in terms of the social relations between
researchers in RCTs. We use social network analysis to study the impact of interactions between RCTs on treatment success.
Our dataset consists of 280 phase III RCTs conducted by the NCI from 1955 to 2006. The RCT networks are formed through
trial interactions formed i) at random, ii) based on common characteristics, or iii) based on treatment success. We analyze
treatment success in terms of survival hazard ratio as a function of the network structures. Our results show that the
discovery process displays power law if there are preferential interactions between trials that may stem from researchers’
tendency to interact selectively with established and successful peers. Furthermore, the RCT networks are ‘‘small worlds’’:
trials are connected through a small number of ties, yet there is much clustering among subsets of trials. We also find that
treatment success (improved survival) is proportional to the network centrality measures of closeness and betweenness.
Negative correlation exists between survival and the extent to which trials operate within a limited scope of information.
Finally, the trials testing curative treatments in solid tumors showed the highest centrality and the most influential group
was the ECOG. We conclude that the chances of discovering life-saving treatments are directly related to the richness of
social interactions between researchers inherent in a preferential interaction model.
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Introduction
Randomized controlled clinical trials (RCT) are widely
considered one of the most important vehicles of discovery of
new treatments. RCTs have been credited with considerable
improvement in health outcomes resulting in a significant increase
in life expectancy for conditions such as cancer, which is the topic
of this paper [1–7].
We have previously shown that the success of new treatments in
cancer does not fit the random normal distribution curve [8]. We
found that new treatments were, on average, slightly superior to
standard treatments, bringing about small or moderate advances,
with occasional discovery of breakthrough interventions; a pattern
of therapeutic discovery that fits a power law distribution (figure 1)
[8]. In general, power law distributions describe many natural and
man-made phenomena such as the population of cities, the word
frequency in a manuscript, the citations of a scientific paper, etc.
[9,10]. The significance of the power law finding in therapeutic
discovery arises from the scale free property of the distribution,
which implies that, regardless of the number of controlled trials
performed, the discovery of new treatments is described by the
same power law.
While the power law appears to provide a credible mathematical
description of the overall pattern of treatment success, it is not clear
what exact mechanism can explain how power law actually works.
We have previously argued that trials operate on the borderline of
success and failure due to the principle of equipoise [11],which
implies that discovery remains possible only if RCTs are performed
when there is substantial uncertainty with respect to the relative
merits of interventions to be tested. However, if that were the only
explanation,the distributionof treatment successeswould be random
i.e. the pattern of therapeutic discovery would fit the normal
distribution, which we found it was not the case. In reality,itcouldbe
expected that based on the tremendous amount of effort and money
spentondiscoveryofnewtreatments,thenumberofsuccessfulRCTs
would be significantly greater than the number of unsuccessful ones,
resulting in a skewed distribution. The equipoise hypothesis does not
provide explanation forthe factthat new treatmentsareslightlymore
superior to the old ones, as it does not take into account researchers’
efforts to develop new more successful treatments [8]. In this paper,
we argue that the mechanism responsible for the observed pattern in
therapeutic discovery is the social interactions between the
researchers who conduct clinical trials (but who do have to work
under the ethical requirement of equipoise).
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18060The process of discovery that characterizes scientific progress is
inherently a social enterprise. The pursuit of future discoveries
depends upon understanding of the existing and ongoing research
[12–14]. This characteristic of the scientific discovery process has
been most memorably captured in the metaphor expressed by
Isaac Newton: ‘‘If I have seen a little further it is by standing on the
shoulders of Giants’’ [15]. Therefore, the process of scientific
discovery depends on the interactions between past and current
researchers, as well as institutions and the wider scientific
community that sanctions the results of a given research endeavor
and ultimately ensures that it is accepted [12–14]. The same
process of social interactions applies to clinical trials, particularly
well-designed RCTs.
A trial design is largely attributed to knowledge and information
acquired in earlier trials. Investigators tend to interact with
colleagues in their immediate environment [16] and/or make use
of scientific journals and meetings [17,18] to share knowledge as
well as trial successes and failures among the members of scientific
community. However, if testing of new (therapeutic) ideas is to
occur, the researchers’ personal representations must be further
formalized. For example, in the U.S., most RCTs that are not
conducted by industry are performed under the auspices of the
National Cancer Institute (NCI) that support the co-operative trial
infrastructure. All proposals aimed at testing new promising
treatments are vetted and ultimately funded through the
framework of the NCI co-operative groups (COGs).
We postulate that the social interactions between members of
the NCI COGs drive the development of therapeutic discovery for
malignant diseases. If this is the case, then the analysis of explicit
interactions between RCTs ought to shed some additional light on
the treatment discovery process in cancer, in particular, explain
the power law pattern of treatment success. Studying the RCTs in
such a way is expected to help understand the process of treatment
discovery within the entire RCT system that ultimately may help
improve health outcomes.
Methods
Dataset
We used a data set reported in detail elsewhere [8]. This data set
involves 216,451 patients and consists of 624 phase III RCTs
sponsored by the NCI COGs conducted and published from 1955
to 2006 [8]. We limit our analysis to 280 out of the 624 trials that
considered survival as their primary outcome. In these trials
researchers explicitly set out to improve survival by testing new
therapeutic agents. These trials used superiority design aiming to
address the question if one treatment is superior to another. There
were no non-inferiority trials in which success would have been
deemed as one treatment being equal or non-inferior to another.
Treatment discovery
In general, treatment success in cancer can be measured by [8]: (1)
assessing the proportion of statistically significant trials favoring new
or standard treatments, (2) determining the proportion of trials in
which new treatments are considered superior to standard treatments
based on investigators’ overall judgments, and (3) quantitatively
synthesizing data for main clinical outcomes (overall and event-free
survival). Each of these measures has its advantages and disadvan-
tages,but,atleast,inlife-threateningdiseasessuchascancer,assessing
survival seems to be the key determinant of true success rate. Hence,
we consider that the best metric of research efforts to discover new,
effective treatments is improvement in patients’ outcomes. In this
work, we choose the survival hazard ratio (HR), as reported in each
RCT, as the crucial metric of treatment success. That is, successful
trials are considered as those with a statistically significant survival
hazard ratio with value greater than 1 (at p value #0.05).
Social Networks
As per our hypothesis, there exists a relationship between RCT
interactions and the treatment discovery process. If that is the case,
then trials with extensive interactions are expected to be associated
with improvements in survival. We used social network analysis to
study the effects of these socials interactions on treatment success.
An RCT network is represented as a set of nodes, each node
denoting a trial, and a set of ties, each tie denoting an interaction
between trials. Since it is impossible to determine precisely how
RCTs communicate, we assume that RCT interactions could be
formed in three ways: (1) based on shared characteristics between
trials, (2) based on the treatment success of trials, and (3) at
random. We then analyze how treatment success is related to its
connections in each type of network.
Model 1: RCT interactions based on shared
characteristics. The first model postulates that RCT
interactions are confined between trials in related fields. Therefore,
interactions between trials occur (a) at the level of each COG (which
ultimately proposes the trial to be carried out among the member
institutions) (figure 2a), (b) type of disease, since the treatment
discovery is typically a disease-oriented process (i.e. breast cancer,
gastrointestinal cancer, gynecologic cancer, etc.) (figure 2b), and (c)
type of treatment, which defines the category of therapeutic agents
(i.e. adjuvant, curative/definitive, induction, etc.) (figure 2c).
Ultimately, there are many levels of trial interactions such as the
investigator’s institution, the study section, the funding source, etc.
However, allthesetypes ofinteractionseventually filter to interactions
at the level of COG, type of disease and treatment, which we believe
represent the most salient aspects of the RCT system.
The combination of all possible interactions generates 7
different networks, referred to as shared characteristics networks
in the rest of the manuscript. In our analysis we have omitted the 3
networks created using interactions at the level of single
characteristics since these networks are comprised by isolated
groups of trials corresponding to each cooperative group, type of
disease, or treatment.
Model 2: RCT interactions based on the previous
treatment success. The second model theorizes that RCTs
interact selectively across the RCT spectrum, specifically, that
interactions between the most successful trials are favored (‘‘success
Figure 1. Distribution of treatment success in oncology.
Distribution of treatment success in oncology expressed as survival
hazard ratio (HR), where higher HR indicates more successful
treatments. The curve illustrates slightly increased number of successful
treatment consisted with a power law function.
doi:10.1371/journal.pone.0018060.g001
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to interact mostly with established and well known peers. A model
for network formation based on such interactions is the preferential
attachment model [19,20]. According to this model, nodes are
connected at randomwith a bias towards themost connected nodes.
In our setting, we argue that the most connected nodes are
represented by the most successful trials, particularly those with
HR.1a n dp value,0.05. Therefore, we construct the RCT network
assuming that the probability of an RCT receiving a tie is
proportional to the success of the RCT as measured in terms of
survival hazard ratio (HR), and the statistical significance of the
reported results as indicated by the p value. We call this network the
preferential attachment network in the rest of the manuscript.
The preferential attachment RCT network is formed iteratively,
starting with a small number of RCTs. At each iteration, a new
RCT is added to the network and a predetermined number of
interactions with existing trials are imposed. The probability that
an existing trial, i, receives a tie depends on its success during the
previous testing in RCTs and is expressed in terms of survival
hazard ratio (HR) and statistical significance:
Pi~
HRi(1{pvaluei)
Pn
j~1 HRj(1{pvaluej)
ð1Þ
where the summation is over all the nodes in the network at the
current iteration, n.
Model 3: Random RCT interactions. The third and final
model, assumes that trials interact at random. We construct five
sets of Erdos-Renyi [21] random networks each of which is
composed of 280 nodes representing each of the trials. The
average number of ties in each set matches the average number of
ties in the first 5 networks (4 constructed on the basis of shared
characteristics and 1 on the basis of preferential attachment). The
random networks are then compared with the shared
characteristics and the preferential attachment networks.
Network topology
To identify the topology of the RCT networks in order to
compare the different structures, we computed the three most
important measures of connectivity for each network: the average
Figure 2. Network configurations of social interactions of RCTs in cancer*. Each node in the network represents a trial cited as the triplet
denoting the COG it belongs to, the type of disease and treatment it studies. The networks have been constructed considering relationships between
COG (a), type of disease (b), type of treatment (c), and the conjunction of all possible interactions (d). *For illustration reasons, only a limited number
of RCTs is shown.
doi:10.1371/journal.pone.0018060.g002
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the global clustering coefficient, and the degree distribution. The
shortest path distance shows how accessible the network is; small
values are desirable for a tightly connected network. The global
clustering coefficient measures the overall tendency of nodes to
form clusters in which the connections of one node are themselves
connected to each other forming distinct groups. The degree
distribution is the distribution of the nodes’ connections in the
Table 1. Network topology characteristics for undirected networks.
Network
Average shortest
path distance
Global Clustering
coefficient Number of nodes Average number of ties
Group and Disease 1.80 ; 1.74* 0.68 ; 0.25* 279 71
Group and Treatment 1.57 ; 1.56* 0.73 ; 0.43* 279 120
Disease and Treatment 1.67 ; 1.61* 0.77 ; 0.38* 279 106
Group, Disease and Treatment 1.52 ; 1.52* 0.69 ; 0.47* 279 133
Preferential attachment 1.88 ; 1.87* 0.24 ; 0.13* 279 36
The asterisk corresponds to measures of random networks with the same number of nodes and ties.
doi:10.1371/journal.pone.0018060.t001
Figure 3. Connectivity distributions for different network configurations. The connectivity distribution for the shared characteristics
network of group, treatment and disease (a) is described by a single scale distribution. The connectivity distribution for the preferential attachment
network (c) is described by a power law distribution (The power law is of the form
a{1
xmin
x
xmin
   {a
, with a=2.83, xmin=27, and p
value=0.138). For brevity, we do not include the shared characteristics networks generated by the: group, treatment; group, disease; disease,
treatment.
doi:10.1371/journal.pone.0018060.g003
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in network analysis since it shows the number of interactions each
node (RCT) has. A glossary defining each of these terms is
provided at the end of the manuscript.
Node analyses
Not all the nodes in a network are of the same importance.
Based on their position in the network, some nodes can interact
more easily with other nodes, or are on many short paths
between other pairs of nodes. These two properties are captured
by the centrality measures of closeness and betweenness.
Closeness measures the average distance a node has to all others
in the network – shorter values mean greater ease of interaction
with all others. Betweenness measures how important a node is in
connecting other nodes [22] . Other centrality measures of
importance are authority and hub [23]. Authority is a centrality
measure that shows how influential a node is in the network
while, a node is considered a hub if it is connected with many
authorities. By computing centrality measures in the RCT
networks we can identify the most central nodes and analyze
their characteristics. A final node level measure is the local
clustering coefficient. It measures the extent to which a node’s
connections are themselves connected to one another. High
values mean the node is a member of a tightly knit cluster of
nodes; low values, the opposite.
Results
Network topology
To identify the topology of the RCT networks we computed the
average shortest path distance, the global clustering coefficient,
and degree distribution for each network. We then compared
these values to the corresponding values of a random network with
the same number of nodes, and average number of ties.
Table 1 summarizes the values of global clustering coefficient
and average shortest path distance for the networks studied and
their corresponding random networks. The networks have been
treated as undirected but within the constraint of time flow (i.e.,
only trials performed later in time could connect to trials
conducted earlier in time). The preferential attachment network
Figure 4. Average HR as a function of node connectivity for trials reporting survival outcomes. The plots (a, b, and d) show that there is
no direct relationship between treatment success and connectivity. However, for the preferential attachment network (c), there is an increasing trend
relationship between treatment success {as measured by survival HR (hazard ratio)} and connectivity arguing that better connected researchers may
discover more life-saving treatments! For brevity, we do not include the networks generated by the shared characteristics: group, treatment; group,
disease; disease, treatment.
doi:10.1371/journal.pone.0018060.g004
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average path distances, comparable to the distances in the
corresponding random graphs but, global clustering coefficients
much higher than their corresponding random networks (Table 1).
Such a pattern of connectivity corresponds to small world networks
[24]. Characteristics of small world networks are: (a) small average
shortest path distances, (b) large global clustering coefficients (larger
than the corresponding random network), and (c) connectivity
distributions described by either a scale free, broad scale or single
scale distribution [25,26]. The shared characteristics networks are
small world networks with single scale connectivity distributions
(figure 3a), while the preferential attachment network is a small world
network with a power law (scale free) distribution of the form
a{1
xmin
x
xmin
   {a
(figure 3c). Since there is an uncertainty associated
with the formation of the preferential attachment network we run 250
simulations out of which 225 have power law connectivity distribution
with (a(mean=2.8,variance=0.18),xmin (mean=26, variance=4.5)andp
value.0.1 based on the algorithm presented in [10], which indicates
that when pv a l u e .0.1, the power law is a plausible hypothesis for the
data). The remaining 25 networks had pv a l u e ,0.1.
Thus, the process of discovery of new therapeutics in cancer
under the NCI umbrella, represented either as a shared
characteristic network or a preferential attachment network, fits
a pattern of connection that can be described as a small world
network in which each trial is connected to any other trial in the
network through just a few ties. This finding is probably not
surprising since previous work showed that the structure of
scientific collaboration networks often takes the form of small
world networks [27], but it has never been studied in the setting of
clinical research.
Treatment discovery
We hypothesized that a positive relationship exists between the
extent of a trial’s interactions and treatment success. That is, the
trials with many interactions will have greater treatment success
than trials with few interactions. To test this hypothesis, we plotted
the average value of survival hazard ratio for nodes as a function of
their connectivity (degree). Figure 4a depicts the results for the
shared characteristics network, while figure 4c shows the results for
the preferential attachment network. Figures 4b,d illustrate the
results for the corresponding random networks. Both figures 4a
and 4c suggest that it is impossible to predict a particular trial’s
success based on its connectivity (degree). Furthermore, if RCT
interactions are actually formed based on shared characteristics,
then, despite the small world connectivity, the relationship
between treatment success and RCT interactions is random with
overall success rate slightly above 50% [8,11]. Thus, trial success
confined within the interactions at the level of the group,
treatment, or disease is only slightly associated with the extent of
connectivity. However, when trial success (HR) is plotted for the
preferential attachment model (figure 4c), a different pattern
emerges: the greater the extent of connectivity, the bigger is
treatment success (HR) i.e. the higher are the chances that
researchers discover new life-saving treatments! While this is a very
intriguing result which can best explain the skewed distribution
Figure 5. Average HR as a function of centrality measures for the shared characteristics network: group, disease, treatment. There is
no identifiable pattern between survival HR and the various centrality measures.
doi:10.1371/journal.pone.0018060.g005
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restrictions imposed on our model.
To address the latter issue, we assess the relationships between
treatment success and other centrality measures- the results that
we believe could not be obviously predicted from the preferential
attachment model. We, therefore, express treatment success as a
function of closeness, betweenness, and local clustering coefficient.
As expected, there is no identifiable pattern in the case of shared
characteristics networks (figure 5). For the preferential attachment
network, however, there is an increasing trend between treatment
success and the measures of betweenness and closeness and a
decreasing trend between treatment success and local clustering
coefficient (figure 6). One interpretation of this finding is that those
trials (researchers) with easy access to information (those with high
betweenness and closeness) are more successful than others, while
those researchers who tend to interact within a closed group (as so
have high local clustering coefficients) are less exposed to good
ideas/information and so are less successful [28].
Node analyses
To identify characteristics of individual nodes in the network,
we used the centrality measures described in the Methods section.
Table 2 summarizes the characteristics for the nodes (trials) that
present the highest centrality measures as well as the average
survival HR values. We are interested in identifying the
characteristics that make trial(s) distinctive.
It is interesting to note that, regardless of the approach used to
form the RCT networks, the nodes with the highest centrality
measures were the ones that studied curative/definitive treat-
ments (Table 2) in solid tumors. This makes intuitive sense since
large solid tumors (as opposed to hematological malignancies) can
rarely be cured, and one would expect that trials attempting to
test curative or more definitive treatments for these diseases
would attract more attention from other investigators. Similarly,
trials that were considered most central are the trials performed
by ECOG (Eastern Cooperative Group) and studied curative/
definitive type of treatments. This is probably not surprising since
the ECOG is the largest NCI COG and is likely to have more
influence on the trajectory of treatment discoveries than other
NCI COGs. Likewise, curative/definitive treatments for solid
tumors attracted more attention than more established therapies
for lymphomas and other hematological malignancies. It should
be noted that these treatments may not necessarily be less
successful. Effective treatments for hematologic malignancies
were discovered during early existence of the COG and hence it
is not surprising that they received less attention during later
decades of testing in RCTs conducted by the various COGs. This
is particularly true as no major breakthroughs in the management
of these diseases within the COG setting has occurred since the
early 1970s.
Discussion
One of the underlying premises of clinical research enterprise,
including findings of new successful treatments, is that better
scientific understanding should translate into improvement in
patients’ outcomes such as better survival. Such better scientific
understanding is typically ensured via extensive social scientific
Figure 6. Average HR as a function of centrality measures for the preferential attachment network. There is an increasing trend
between treatment success and the measures of betweenness and closeness (a, b), which implies that treatment success is not only a function of
connectivity but also a function of node centrality and ease of access to relevant information. However, there is a decreasing trend between
treatment success and local clustering coefficient (c). We speculated that nodes with high clustering coefficient are those which tend to interact
within a closed group of trials (‘‘silos’’ of information exchange) and consequently are the least successful.
doi:10.1371/journal.pone.0018060.g006
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of knowledge through scientific literature) and current researchers.
We argue that the interactions between researchers who
conduct clinical trials are responsible for previously reported
patterns in therapeutic discovery [8]. That is, treatment success in
cancer is described by a power law distribution in which the
majority of trials operate on the borderline of success and failure,
while few trials are very successful [8].
Modeling interactions between researchers is a rather challeng-
ing process. We proposed three different approaches. First, we
assume that RCT interactions are confined between trials in
related fields such as cooperative group, type of disease or
treatment (network with ‘‘shared characteristics’’). Then, we
generated RCT networks considering treatment success as the
driving force of interactions. Finally, for comparison purposes, we
assumed that RCTs interact at random.
Our results indicate that the networks created based on shared
characteristics as well as those created based on treatment success
aresmallworldnetworks.Smallworldshave been showntodescribe
otherscientificcollaborationnetworks [27].However, this isthefirst
time that they have been shown to apply to networks formed in
clinical settings. The importance of the small world finding is that all
trials are connected through a small number of ties enhancing the
argument that treatment discovery is a social enterprise.
Table 2. Characteristics of the most central trials.
Network Measure Group Disease Treatment Av. HR
Group, Treatment,
Disease
Betweenness
Max=0.006
ECOG Leukemia Definitive
* 1.22
Closeness
Max=0.75
ECOG GI Definitive
* 1.22
Authorities
Max=0.08
ECOG GI(8/10); GYN(2/10) Definitive
* 0.97
Hubs Max=0.08 ECOG GI(8/10); GYN(2/10) Definitive
* 0.97
Random network
based on the
Group, Treatment,
Disease network
Betweenness
Max=0.002
RTOG Lung Definitive
* 0.98
Closeness
Max=0.69
ECOG Lung Definitive
* 0.98
Authorities
Max=0.06
RTOT (3/10);
ECOG (5/10);
GOG (1/10);
SWOG (1/10)
GI(3/10); Lung (2/10);
GYN (2/10);
H&N Leukemia
Definitive
*(6/10);
Adjuvant (2/10);
Supportive(1/10);
Other (2/10)
0.96
Hubs Max=0.06 RTOT (3/10);
ECOG (5/10);
GOG (1/10);
SWOG (1/10)
GI(3/10); Lung (2/10);
GYN (2/10);
H&N Leukemia
Definitive
*(6/10)
Adjuvant (2/10)
Supportive(1/10)
Other (2/10)
0.96
Preferential attachment Betweenness
Max=0.04
RTOG Prostate Definitive
* 2.82
Closeness
Max=0.66
ECOG Lung Definitive
* 2.31
Authorities
Max=0.18
ECOG Lung Definitive
* 2.31
Hubs Max=0.18 ECOG Lung Definitive
* 2.31
Random network
based on the
Preferential
attachment
network
Betweenness
Max=0.068
SWOG GI Adjuvant 0.75
Closeness
Max=0.554
SWOG GI Adjuvant 0.75
Authorities
Max=0.089
ECOG (5/10);
SWOG (2/10);
NCCTG (1/10);
CALGB (1/10);
CHOG (1/10)
GI (3/10); CNS (2/10);
Lung (2/10);
Leukemia (1/10);
Melanoma (1/10);
Breast (1/10)
Definitive
*(5/10);
Adjuvant (3/10)
Maintenance (1/10) Other
1.10
Hubs
Max=0.089
ECOG (5/10);
SWOG (2/10);
NCCTG (1/10);
CALGB (1/10);
CHOG (1/10)
GI (3/10);
CNS (2/10);
Lung (2/10);
Leukemia (1/10);
Melanoma (1/10)
Breast (1/10)
Definitive
*(5/10)
Adjuvant (3/10)
Maintenance (1/10) Other
1.10
For brevity, we do not include the networks generated by the shared characteristics: group, treatment; group, disease; disease, treatment. The numbers in parentheses
denote the memberships of each component in the group of nodes that present the same centrality measures.
doi:10.1371/journal.pone.0018060.t002
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(figures 4d), or on a shared characteristic basis (figure 4a, 4b),
dense interactions do not appear to translate into treatment
success as measured in terms of improvement in cancer survival.
On average, new treatments are only slightly superior to old ones:
a finding explained by the equipoise hypothesis, which suggests
that the requirement for uncertainty in clinical trials is what drives
the RCT system, but which also predicts that new treatments are
not very likely to be much more successful than the established
ones [11,29,30]. However, the equipoise hypothesis does not
explain the existence of a comparatively greater proportion of the
small number of very successful trials among newly developed
treatments [8].
A different picture emerges for the preferential attachment
network: if trials are connected on an individual treatment success
basis (figure 4c), then while for the majority of the trials the
relationship between treatment success and connectivity seems
random and governed by equipoise (figure 4c for degrees less than
100), there are few trials for which there is a proportional
relationship between connectivity and success rate (figure 4c for
degrees greater than 100). This finding agrees with our previously
reported results that showed that treatment success in cancer is
distributed as a power law function with the majority of the trials
operating on the borderline between success and failure, and a
small number of very successful trials [8]. The preferential
attachment model provides an underlying mechanism that could
explain this overall pattern of therapeutic discovery.
We believe that the mechanism responsible for the reported
pattern of treatment discovery in cancer relates to the social
interactions between RCTs as it stems from researcher’s tendency
to interact selectively with established and successful peers. It
should be noted that the social interactions do not violate the
equipoise requirement, rather they complement it. The findings
indicate that the overall cancer RCT system maintains equipoise
via unpredictability in the results at any individual trial, while
providing the avenue for the researchers to increase their odds to
discover new successful treatments which will go beyond 50:50
odds predicted by the original equipoise hypothesis. We, therefore,
argue that the social network analyses along with ethical analyses
of equipoise presented in this paper provide further understanding
of the principles that drive the treatment discovery process.
Our research has some limitations. The main limitation is that
we have used interactions between RCTs as a proxy of the actual
interactions between COG researchers. We had no way to identify
the multitude of factors that actually influence researchers to
determine why and what exactly they choose to study. Neverthe-
less, in the final analysis, many of these formal and informal
mechanisms of interactions do converge to the factors we used in
the analysis presented here. Second, we studied the process of
social interactions within the closed system of NCI COGs. In
reality, the NCI COG researchers interact with the outside
biomedical research community and that may influence the types
of research the NCI COG performs. However, the NCI COG is a
very influential organization, and while it is probably influenced
by outside factors, to some extent, it has its own platform for
research development that, we believe, is accurately reflected in
our analysis. To address the issue of the impact on non-NCI
sources on the type of research performed by the NCI, we
attempted to perform the citation analysis of RCT trials used in
our analysis. Unfortunately, this proved unfruitful as the most
publications did not cite the research leading to their proposals,
thus making it impossible to create meaningful social interactions
patterns.
We conclude that the treatment discovery process in RCTs
could be explained by a small world network model according to
which each trial is connected to any other trial in the network
through a small number of steps. Furthermore, we present
intriguing results that the richer the social interaction, as reflected
in ease and importance of connections (closeness and between-
ness), the greater the chance is that researchers may discover new
life-saving treatments when connections are formed on the basis of
preferential attachment. At the same time, trials which interact
within ‘‘information silos’’ (as reflected by high local clustering
coefficients), are associated with low survival HR arguing that the
limited information exchange may be detrimental to the treatment
discovery process!
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